Cost-Effectiveness of First- and Second-Step Treatment Strategies for Major Depressive Disorder A Rapid Review

Article Health Care Sciences & Services

Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews

Chantelle Garritty et al.

Summary: The study aims to develop guidance to support the conduct of rapid reviews, with 26 recommendations presented based on survey results. These recommendations will help synthesize evidence for urgent health issues, but the guidance will need to be updated as new evaluations for some RR methods are conducted due to the current lack of available evidence.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant

Kokuvi Atsou et al.

Summary: The study compared the cost-effectiveness of vortioxetine, levomilnacipran, and vilazodone for MDD patients who had inadequate responses to their first AD, finding that vortioxetine had incremental QALY gains and was both dominant and cost-effective compared to the other two medications. Sensitivity analyses showed consistent results, with vortioxetine remaining dominant and cost-effective. The inclusion of cognition outcomes reduced the ICER, providing additional support for considering vortioxetine for patients requiring a switch of MDD treatments.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)

Add to Collection

Article Economics

The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)

Paul E. Greenberg et al.

Summary: The number of US adults with major depressive disorder (MDD) increased by 12.9% between 2010 and 2018, resulting in a 37.9% increase in the economic burden. The largest growth in costs was observed in workplace costs. Despite the overall increase in the number of MDD patients, the direct cost per individual decreased, and the proportion of treated patients remained stable, indicating unmet treatment needs. Further research into MDD treatment services is warranted.

PHARMACOECONOMICS (2021)

Add to Collection

Article Medicine, General & Internal